Immunological reactivity between chimeric cattle twins. I. Homograft reaction

Transplantation
D Emery, P McCullagh

Abstract

The response of chimeric calves to grafts of cotwin skin was examined both by direct observation of the fate of the graft and by collection of lymph from the lymph node which drained the grafted area. Whilst grafts of body skin exchanged between 16 pairs of twins survived for longer periods than did grafts transferred between unrelated calves, all of the former had been rejected after 10 weeks. Secondary grafts of cotwin body skin were rejected significantly faster. In contrast, grafts of auricular skin exchanged between cotwins survived indefinitely in some instances despite the rejection of simultaneously transferred body skin. The magnitude of the blast cell response observed in efferent lymph in the case of grafts exchanged between cotwins was generally intermediate between that observed in responses to allografts and control autografts. However, an early peak of blast cell response which occurred some 50 hr after placement of allogeneic grafts was not observed in response to cotwin grafts.

Citations

Oct 23, 2004·Microsurgery·Jamal A NazzalW P Andrew Lee
Mar 29, 2007·European Journal of Immunology·Bin LuoColin C Anderson
Apr 18, 2012·Chimerism·David P Al-Adra, Colin C Anderson
Mar 24, 2005·Nature Immunology·Ronald H Schwartz
Aug 31, 2002·Journal of Hematotherapy & Stem Cell Research·Laurence E ShieldsMagnus Westgren
Jan 7, 2004·Plastic and Reconstructive Surgery·François PetitW P Andrew Lee
Apr 9, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·William F N ChanColin C Anderson
Sep 20, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·William F N ChanColin C Anderson
Jan 1, 1982·Animal Blood Groups and Biochemical Genetics·D J PringnitzW H Stone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.